Risk of Infection Associated With Ibrutinib in Patients With B-Cell Malignancies: A Systematic Review and Meta-analysis of Randomized Controlled Trials-Reference-Cited by-同舟云学术

Risk of Infection Associated With Ibrutinib in Patients With B-Cell Malignancies: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Published:2020-02 Issue:2 Volume:20 Page:87-97.e5
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Ball Somedeb^ORCID,Das Avash,Vutthikraivit Wasawat^ORCID,Edwards Peggy J.,Hardwicke Fred,Short Nicholas J.,Borthakur Gautam,Maiti Abhishek

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference33 articles.

1. The 2016 revision of the World Health Organization classification of lymphoid neoplasms;Swerdlow;Blood,2016

2. 2016 US lymphoid malignancy statistics by World Health Organization subtypes;Teras;CA Cancer J Clin,2016

3. Ibrutinib for B cell malignancies;Novero;Exp Hematol Oncol,2014

4. The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis;Leong;Blood,2016

5. Current understanding of bleeding with ibrutinib use: a systematic review and meta-analysis;Caron;Blood Adv,2017

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chronic Lymphocytic Leukemia: Management of Adverse Events in the Era of Targeted Agents;Cancers;2024-05-24

2. Infectious Complications of Venetoclax Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis;Blood Advances;2023-12-28

3. Infectious complications among patients receiving ibrutinib for the treatment of hematological malignancies;American Journal of Health-System Pharmacy;2023-09-07

4. Vaccinations in hematological patients in the era of target therapies: Lesson learnt from SARS-CoV-2;Blood Reviews;2023-07

5. Efficacy of front‐line immunochemotherapy for transplant‐ineligible mantle cell lymphoma: A network meta‐analysis of randomized controlled trials;Cancer Medicine;2023-06